Lymphoma & Plasma Cell Disorders
Four case examples illustrate the important role of multidisciplinary medical care for the optimal long-term care of patients with follicular...
CHICAGO – R2 produced responses in patients who were refractory to rituximab or both lenalidomide and rituximab at baseline.
CHICAGO – There was “oohing and aahing” over results showing high response and survival rates for combined rituximab, lenalidomide, and ibrutinib...
The alkylator-free regimen of daratumumab plus lenalidomide and dexamethasone appears safe and effective for patients who are ineligible for stem...
At 3 years, the rate of progression-free survival was 91% in patients with smoldering multiple myeloma who were randomized to lenalidomide and 66...
The objective response rate of 85% among 33 heavily pretreated patients suggests “promising efficacy.”
GLASGOW – A retrospective, real-world study suggests that older, fit patients can tolerate an intensive treatment regiment for primary central...
GLASGOW – Dr. Loretta Nastoupil of the MD Anderson Cancer in Houston said that toxicity in CAR T-cell therapy “is something we don’t talk about as...
NEWPORT BEACH, CALIF. – Dr. John F. DiPersio discusses preclinical research testing CAR T-cell therapies in T-cell malignancies.